Home

eOncology Report

Summer 2011

ASCO: CT lung screenings show a benefit

Suspicious findings were three times greater with CT scans than with chest X-rays in a large national study.
[ Rachel Sanborn, M.D., co-medical director, Providence Thoracic Oncology Program ]

ASCO: Combo study brings mixed results

A trial testing apricoxib with erlotinib showed longer survival in younger patients with metastatic lung cancer, but failed to meet its goal.
[ Rachel Sanborn, M.D., co-medical director, Providence Thoracic Oncology Program ]

The promise of statins as a chemopreventive

A clinical trial examines whether statins will inhibit a recurrence in patients with resected stage I or II colorectal cancer.
[ Anupama Kurup, M.D., medical oncologist, Providence Oncology and Hematology Care Clinic ]

Multidisciplinary cancer clinics grow

Providence Cancer Center’s one-stop clinics now cover lung cancer, gynecologic cancers, dysplasia, survivorship and palliative care.
[ Lyn Glenn, M.N., F.N.P., A.O.C.N., director, Cancer Clinical Programs ]

“Survivorship and Quality of Life”

Researcher, social worker and cancer survivor Brad Zebrack, Ph.D., discusses how professionals can help the growing number of U.S. cancer survivors. Registration required.

Providence researchers earn national grants

Researchers Michael Gough, Ph.D., and Andrew Weinberg, Ph.D., have received $450,000 and $935,000 respectively to study immunotherapies that will treat metastatic breast cancer and prostate cancer.

After treatment: the medicine of survivorship

Providence Cancer Survivor Clinic provides treatment plans for patients dealing with the lingering physical and psychological legacies of cancer.
[ Jennifer Weprin, M.S.N., F.N.P.-B.C., nurse practitioner, Providence Cancer Survivor Clinic ]

Who’s publishing and presenting

Providence Cancer Center’s oncologists, surgeons and researchers are traveling the country and sometimes the globe to share their expertise.

Photo gallery: Providence Cancer Center luncheon

The annual event continues to draw a packed house. Biblical scholar and prostate cancer survivor John R. Kohlenberger III was this year’s keynote speaker.

Register now: Head and neck conference

“Technological Advances in Head and Neck Oncology and Craniomaxillofacial Surgery” in Portland July 22-24

Ipilimumab advances melanoma treatment

Brendan Curti, M.D.
Medical director, Providence Melanoma Program

Of the three main types of skin cancer, melanoma presents the greatest public health problem, with incidence doubling approximately every 20 years in the United States.

The United States saw more than 68,000 new diagnoses of invasive melanoma in 2009 and 8,100 deaths from the disease. Disease-specific survival curves in all stages of melanoma have a negative slope, implying that metastatic disease can originate from thin primary lesions and that metastatic melanoma can develop many years after the initial diagnosis.

Up to 10 percent of patients presenting with stage I melanoma (primary site less than 1 mm in depth and no nodal involvement) will die as a consequence of metastatic disease within 10 years.

↑ Back to top | Home | Archives

Providence Cancer Center administration
Providence Portland Medical Center
4805 NE Glisan St., Portland, OR 97213

Follow and interact with us
on Facebook and Twitter

Share via


Subscribe now eCardioVascular Beat \| eNeuro \| eOncology Report

eOncology Report

Summer 2011

More